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Introduction 
The efficacy of Highly Active Antiretroviral Therapy (HAART) 
improved over time since it was introduced in 1996, progressively 
yielding better survival rates among treated HIV patients [1-4]. Several 
factors have been associated with such an improvement in recent years: 
the availability of drugs more specifically and selectively targeted to 
their retroviral moiety, with a better pharmacokinetic and toxicity 
profile [5-9];
 
the introduction of low-pill burden regimens, favoring 
long-term adherence [10-13]. Most of presently available data on 
increased HAART efficacy came either from Randomized Controlled 
Trials (RCTs), usually comparing different regimens on parallel groups 
of patients [14-17], or from longitudinal cohort studies, observing 
selected patients’ populations over time [18-21]. Less is known about 
the efficacy and durability of HAART in unselected patients starting 
their first line of therapy in ordinary clinical settings at different 
calendar years [22-24]. With the aim of comparing the efficacy and 
tolerability of first-line HAART regimens prescribed in such settings 
over time, we planned a retrospective multicenter investigation on 
patients starting antiretroviral therapy at Italian centers in the Italian 
Coordination Group for the Study of Allergies and HIV infection 
(CISAI) group. 
Patients and Methods 
All of the 26 centers in the CISAI group were requested to collect 
and contribute data at the end of 2008. Adhering sites had to provide 
data on all consecutive patients whose first HAART line was prescribed 
in 1998 and 2006. The first sample year was selected because of its 
proximity to the initial availability of triple antiretroviral regimens, 
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Abstract
Purpose: The evidence suggesting increased HAART efficacy over time comes from randomized trials or cohort 
studies. This retrospective multicenter survey aimed to assess the variation over time in the efficacy and tolerability 
of first-line HAART regimens in unselected patients treated in ordinary clinical settings. 
Methods: Retrospective analysis of data of all patients starting first-line HAART regimens in 1998 and 2006 at 
adhering centers in the Italian CISAI group. 
Results: For the 543 patients included, mean age was 39.1 ± 9.8y in 1998 and 41.0 ± 10.7y in 2006 (p=0.03), 
with a similar proportion of males. Baseline mean log10 HIV-RNA was 4.56 ± 0.97 copies/mL in 1998 vs 4.91 ± 0.96 
copies/mL in 2006 (p<0.001); baseline mean CD4 T-cell counts were 343 ± 314/mm3 in 1998 vs 244 ± 174/mm3 in 
2006 (p<0.001). The following outcomes were significantly improved at 48w in 2006: proportion with undetectable 
HIV-RNA (86.3% vs 58.0%; p<0.001); mean increase in CD4 T-cells count (252 ± 225 vs 173 ± 246; p<0.001); 
HAART modification (20.1% vs 29.2%; p=0.02); HAART interruption (7.3% vs 14.6%; p=0.01); proportion reporting 
optimal adherence (92.2% vs 82.7%, p=0.03). No differences were observed in the prevalence of grade 3-4 WHO 
toxicities (26.4% vs 26.6%; p=0.9). Multivariate logistic regression showed that being treated in 1998 remained an 
independent predictor of virological failure after several adjustments, including adherence.
Conclusions: Our data from patients not included in clinical trials or cohort studies provide an additional 
line of evidence that the effectiveness of HAART significantly improved in 2006. Treated patients, however, were 
significantly older and more frequently late HIV presenters in 2006 than in 1998. 
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as in 1998 most Italian Institutions consistently prescribed triple 
combinations of antiretrovirals to HIV infected patients [25]. The 
second sample year was chosen as the closest one for which follow-
up data at 48w of treatment could be readily available from all sites. 
Inclusion criteria were HIV-1 infection (laboratory diagnosis) and age ≥ 
8y. Patients were excluded if previously treated with a HAART regimen 
for at least 1 month, whereas patients prescribed either mono or dual 
antiretroviral regimens in advance of HAART were considered. Data 
were collected in an electronic database, including demographic and 
clinical characteristics, as age and gender; year of infection; CDC stage; 
number and type of AIDS defining events; diagnosis of opportunistic 
infections at presentation; co-infection with HCV and/or HBV and 
other co-morbidities (renal, cardiac, hematological, neurological, 
other). Type of pre-HAART exposure to antiretrovirals and drug 
associations in the first HAART regimen were reported. Nucleoside 
Reverse Transcriptase Inhibitor (NRTI) backbones were classified as 
thymidine-based, Tenofovir-based or other; Non Nucleoside Reverse 
Transcription Inhibitors (NNRTIs) considered were Efavirenz (EFV) 
and Nevirapine (NVP); Protease Inhibitors (PIs) were categorized 
as Ritonavir (RTV)-boosted, including Lopinavir (LPV), Atazanavir 
(ATV), Indinavir (IDV), Saquinavir (SQV), fos-Amprenavir (fAMP), 
or unboosted, including RTV, IDV SQV, Amprenavir (AMP) or 
Nelfinavir (NFV). Furthermore, Nadir and basal CD4 T-cell counts 
and HIV-RNA levels, basal glycemia, triglyceride and total cholesterol 
levels were also collected, the same parameters being requested at the 
48 w follow-up visit. Other data collected were: reasons for any change 
in prescribed regimens or HAART discontinuation; metabolic and 
toxic events occurring throughout the study period (either derived by 
clinical records or by metabolic parameters). Contributing sites were 
requested to report any WHO grade of the following manifestations 
of drug-induced toxicity: liver enzyme (AST, ALT, gGT) or bilirubin 
elevations, changes in renal function (creatinine, total nitrogen), 
changes in hemoglobin, leukocyte and/or platelet counts, elevations in 
total cholesterol and/or triglyceride levels, gastrointestinal symptoms, 
dizziness/insomnia, rashes or other clinical abnormalities. The local 
Ethics Committee of each contributing centre approved the study 
protocol, proven that all data were treated anonymously. 
Data analysis 
The following outcomes of HAART efficacy were considered: 
percentage of patients achieving viral suppression at 24w and 48w, 
proportion of patients maintaining viral suppression through 48w, 
increase in CD4 T-cell counts at 48w. HIV-RNA levels were reported 
according to sensitivity thresholds in use in reference years (<400 
copies/mL in 1998 and <50 copies/mL in 2006). A composite measure 
to assess AIDS risk prognostic scores was calculated in both groups 
[26]. The AIDS Risk Score is a validated composite index which uses 
CD4 T-cell counts, viral load and age to stratify the probability of 
progressing to AIDS or death after 24w [26]. Adherence was evaluated 
using various methodologies, mostly by the use of questionnaires 
administered during the 48 month follow-up, examining self-reported 
adherence, as described elsewhere [27]. For the purpose of the present 
analysis, available data were merged into a dichotomized measure, 
considering adherence as “optimal” for patients who did not report 
missing any prescribed dose; as “suboptimal” otherwise. For ART 
modification any change of at least one drug in the regimen was 
considered, whereas ART interruption was defined as discontinuing all 
the drugs of the regimen currently received. Toxicity reports were also 
dichotomized in final analyses, being scored as positive when either 
any WHO Grade ≥2 abnormality in hematological and/or biochemical 
values or any WHO Grade ≥2 clinical event occurred. 
Differences in the prevalence of each investigated variable between 
sample years were initially examined using Fisher’s exact test for 
categorical variables and analysis of variance (ANOVA) for continuous 
variables. Multiple logistic regression was used to evaluate potential 
independent predictors of virological failure, which was defined as the 
combined endpoint of either the lack of viral suppression at 24w or the 
rebound (≥1 measurable amplification after reaching undetectability) 
of plasma HIV-RNA before 48w. All variables were tested for inclusion 
in forward stepwise manner and included into the final model only if 
significant (two-tailed p<0.05). A minimum events-to-variable ratio of 
10 was always maintained in multivariate modeling to avoid overfitting. 
Each covariate was tested in its original form or transformed if needed 
(Shapiro-Wilk). In addition, each variable included was tested for 
multicollinearity (Spearman test), for potential interaction and/or 
quadratic/cubic terms. Once a final model was identified, its goodness 
of fit was assessed using the Hosmer-Lemeshow test and its predictive 
power computing the area under the Receiving Operator Characteristic 
(ROC) Curve. The outlier analysis was based upon the calculation of 
Pearson and standardized residuals, the change in Pearson chi-square 
and deviance chi-square, Dbeta influence statistic and leverage (hat 
diagonal matrix) [28].
 
Specifically, we found 21 influential observations 
(4%) and repeated the analysis excluding these, with no substantial 
changes. All analyses were performed using Stata 10.1 (Stata Corp., 
Texas, 2007). 
Results 
Ten sites out of 26 in the CISAI Group provided data on a total 
of 543 patients: 307 treated in 1998; 236 in 2006. The reasons for not 
participating in the study were the following: site not active in 1998 (3); 
site with printed medical records only, inaccessible for retrospective 
collection of data in either year (9); insufficient research personnel 
for complying with the task of retrospective data collection (4). 
Furthermore, 29 of the patients contributed by 3 sites, 9 in 1998 and 




(N=236)       p
Male gender, % 73.0 75.3 0.53
Mean age ±SD, years 39.1±9.8 41.0±10.7 0.03
Drug users, % 40.1 30.4 <0.001
HCV/HBV coinfection, % 38.6 41.0 0.87
Mean CD4 T-cells, mm3 343 ± 314 244 ± 174 <0.001
Baseline CD4 T-cells < 100, % 17.3 20.8 0.30
Baseline CD4 T-cells < 200, % 33.6 40.7 0.09
Baseline CD4 T-cells < 350, % 55.7 80.5 <0.001
Mean log10 HIV-RNA 4.56 ± 0.97 4.91 ± 0.96 0.001
Mean AIDS progression risk ± SD 6.7 ± 9.6 10.2 ± 11.2 0.002
Glycemia mg/dL (95% C.I.) 90.4 (88.0-92.8) 88.1 (85.0-91.2) 0.27
Triglycerides mg/dL (95% C.I.) 159 (135-184)   147 (135-159) 0.34
Cholesterol mg/dL (95% C.I.) 168 (160-175) 162 (156-168) 0.28
Table 1: Selected demographic and laboratory characteristics of the 2 study 
groups.
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information relative to major study outcomes. The characteristics of 
the 2 samples have been reported in Table 1. Some of the baseline 
parameters were similar in the 2 years: male distribution (approximately 
74%); HCV/HBV co-infection (approximately 40%); fasting glycemia 
(approximately 90 mg/dL); mean triglycerides (approximately 150 mg/
dL) and total cholesterol levels (approximately 160 mg/dL). Conversely, 
the 1998 sample, compared with that of 2006, was significantly 
younger (mean age 39.1 ± 9.8 vs 41.0 ± 10.7, respectively), had a higher 
prevalence of drug users (40.1% vs 30.4%), and a lower mean AIDS 
progression risk (6.7 ± 9.6 vs 10.2 ± 11.2), in line with higher levels 
of mean CD4 T-cell count (343 ± 314 in 1998 vs 244 ± 174 in 2006, 
Figure 1b) and lower mean HIV-RNA (4.56 ± 0.97 in 1998 vs 4.91 ± 
0.96 Log10 copies/mL in 2006, Table 1). However, pre-HAART AIDS-
defining events (30.9% in 1998, 29.4% in 2006) and comorbilities other 
than Hepatitis Virus coinfection (32.3% in 1998 and 28.2% in 2006) 
had approximately the same incidence in the 2 sample years. Estimates 
of patients’ adherence were made available from 6 of the 10 sites, for a 
total of 255 evaluable patients, equally distributed between sample years 
(128 and 127 respectively). Optimal adherence (100% of prescribed 
doses) among patients not interrupting their treatment during follow-
up was reported more frequently in 2006 than in 1998 at 48w (92.2% 
vs 82.7%, p=0.03). As shown in Table 2, prescribed HAART regimens 
were very different. In 1998, HAART backbones almost invariably 
included thymidine analogues (93.8%), with an unboosted PI as the 
most common third drug (83.1%), followed by NVP (9.4%). Tenofovir-
based backbones (54.9%) with EFV (30.1%) or a boosted PI (54.7%) 
as the third drug were the most frequent therapeutic options in 2006 
(Table 2). 
After 24w of treatment, viral undetectability was 63.7% in 1998 and 
80.4% in 2006 (p<0.001, Figure 1a); at 48w undetectability dropped to 
58.0% in 1998, whereas it rose to 86.3% in 2006 (p<0.001, Figure 1a). 
Similarly, patients achieving undetectable HIV viremia at least once 
during follow-up were 67.1% in 1998 and 91.3% in 2006 (p<0.001). 
Both groups significantly increased in mean CD4 T-cell counts at 48w 
compared to baseline values (Figure 1b), with a remarkably higher gain 
in 2006 (252 ± 225 vs 173 ± 246, p<0.001, Figure 1b and c). HAART 
was more frequently modified (29.2% vs 20.1%, p=0.02) or interrupted 
for any reason (14.6% vs 7.3%, p=0.01) in 1998 than in 2006. WHO 
grade 3 or 4 toxicity events, however, were evenly distributed in the two 
years (26.4% vs 26.6%; p=0.9, Figure 2a). None of the specific categories 
of events considered, that is gastrointestinal (15 vs 14), hematological 
(5 vs 8), neurological (10 vs 6), hepatic (9 vs 6), dyslipidemia (20 vs 19) 
or rash (6 vs 3) differed significantly between the 2 years (p=0.6, Figure 
2a), whereas renal toxicity was near-significantly more frequent in 1998 
(13 vs 4, p=0.08, Figure 2a). Grade 2 dyslipidemia was more frequent 
in 2006 (23.7% vs 11.5%, p<0.001, Figure 2a). Combined mild and 
severe dyslipidemia was more also frequent in patients using boosted 
vs unboosted PIs (23.0% vs 9.8%; p<0.001). Toxic events occurred with 
the same frequency in both sexes (39.4% in females vs 43.0% in males; 
p=0.5, Figure 2b), whereas patients without any adverse event during 
follow-up were significantly younger (38.4 vs 42.3 years, CI 37.3-39.4 
Figure 1: Annual trends in undetectable HIV-RNA and CD4 T-cell counts.*= 
p<0.001;**= p<0.05. (A): Percentage of patients with undetectable HIV-RNA 
levels at 24 and 48 weeks of HAART in 1998 and 2006. (B): Baseline CD4 
T-cell (left) and 48w CD4 T-cell (right) counts in 307 patients in 1998 and 236 
patients in 2006. Black lines indicate mean values for each group. (C): ΔCD4 
T-cell counts at 24 and 48 weeks of HAART in 1998 and 2006.
Drugs prescribed Group 1998(N=307)
Group 2006
(N=236)      P
NRTIs – no (%) <0.001
   - Thymidine analogues 288 (93.8) 85 (36.2)
   - other analogues 17 (5.6) 150 (63.6)
NNRTIs – no (%) <0.001
  -EFV  5 (1.6) 71 (30.1)
  -NVP 29 (9.4) 12 (5.1)
PIs – no (%) <0.001
  -boosted PIs 6 (1.9) 129 (54.7)
  -unboosted PIs 255 (83.1) 22 (9.3)
NRTI Nucleoside Reverse Transcriptase Inhibitor; NNRTI Non Nucleoside 
Reverse Transcriptase Inhibitor; PI ProteaseIinhibitor; NVP Nevirapine; EFV 
Efavirenz
Table 2: Antiretroviral regimens prescribed in the 2 sample years.
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vs 40.9-43.8, p<0.001). Furthermore, toxic events were extremely more 
frequent in patient changing HAART in both years (69.0% vs 22.3% in 
1998 and 89.1% vs 37.4% in 2006, both p<0.001, Figure 2b), whereas 
they were not associated with interrupting HAART in both years 
(40.0% vs 34.5% in 1998 and 35.0% vs 48.6% in 2006, p=0.5 and p=0.3, 
respectively, Figure 2b). 
The results of the logistic regression investigating potential 
independent predictors of virological failure are shown in Table 3. 
None of the following potentially relevant factors was significantly 
associated with an unsuccessful virological outcome: presence of any 
comorbidity including diabetes (p=0.3); coinfection with HCV and/
or HBV (p=0.10); previous AIDS diagnosis (p=0.14); suffering any 
HAART related toxicity (0.2); baseline HIV viremia (p=0.10); baseline 
CD4 T-cell counts (p=0.5); site of treatment (p=0.3). Multivariate 
analysis confirmed that being treated in 1998 was a significant predictor 
of virological failure (adjusted OR = 3.6; 95%CI 2.2-5.7; p<0.001), as 
being present or past intravenous drug user (adjusted OR = 2.5; 95%CI 
1.6-3.9; p<0.001), changing HAART during follow-up for any reason 
(adjusted OR = 1.8; 95%CI 1.0-3.2; p=0.03). When 48w adherence data 
were included in the final model, halving the number of considerable 
observations, the 2 independent predictors of viral failure were: 
incomplete adherence (OR 11.1; 95%CI: 3.8-33.0, p<0.001) and being 
treated in 1998 (OR=3.1; 95% CI: 1.5-6.3, p=0.003). 
Discussion 
Our multicentric retrospection was aimed to evaluate to which 
extent the results of clinical trials and cohort studies, indicating that 
HAART outcomes are significantly improved in recent calendar 
years [2-4,17-19,21,29], describe what happens in ordinary Italian 
HIV treatment centers, where patients are prescribed their HAART 
regimens at the judgment of attending physicians out of clinical trials, 
cohort studies and other types of controlled direction. Furthermore, by 
comparing demographic and clinical characteristics of patients starting 
their first HAART line at distant calendar years, we tried to outline 
how and to what extent our patients’ populations changed [20,21]. 
Several RCTs demonstrated higher rates of viral suppression in recent 
years, with a remarkable 80% to 90% of patients achieving HIV RNA 
<50 copies/mL after 48 weeks of treatment [17,30,31]. Bartlett et al. 
[17] showed that the proportion of patients in RCTs with HIV RNA 
<50 copies/ml at 48w gradually increased over calendar years. Better 
virological responses were seen despite the enrolment of patients’ 
populations with lower CD4 T-cell counts at entry; furthermore, lower 
CD4 T-cell counts at entry were associated with improved responses 
in some analyses [17,32]. Increased use of NNRTIs and boosted PIs 
were the most significant predictors of potency in more recent HAART 
regimens [17].
A number of cohort studies have in parallel depicted similar 
progresses in the outcomes of ART. Reports from the ICONA cohort 
showed that there was a significant increase in ART success rates in 
Italy between 1998 and 2008 [33]. Patients with CD4 T-cell counts ≤ 
200/mm3 decreased from 14 to 6% and the prevalence of HIV-RNA 
>50 copies/mL similarly decreased from 60% to 40% [33]. The HIV 
Swiss cohort study reported 1-year incremental improvements in 
outcomes between the 2000 -2001 and 2004-2005 time intervals, both 
for patients with plasma HIV RNA <50 copies/mL and for CD4 T-cell 
count gains at 1 year of treatment [19]. An analysis of changes in 
outcomes of patients initiating HAART with a CD4 T-cell count <50 
cells/mm3 in the UK Collaborative HIV Cohort (UK CHIC) found that 
by far the most important predictor of virological suppression at 48 
w was the calendar year for starting ART [34]. In the same cohort, a 
later analysis performed by Bansi et al. [21] in 2010 showed that the 
use of ART resulted in continued improvements from 2000 to 2007.
 
The proportion of patients under follow-up who had CD4 T-cell counts 
<200/mm3 fell from 19% in 2000 to 8% in 2007, while the proportion of 
patients on ART who had viral load <50 copies/mL increased from 62% 
in 2000 to 83% in 2007 [21]. They suggested that changes in virological 
response to the unmodified initial combination of antiretrovirals over 
calendar years may indicate qualitative improvements in HAART 
components [21]. Finally, a retrospective cohort study on ART-
naïve patients was performed from 2001 until 2007 at the University 
of Alabama at Birmingham, USA [35]. This study found significant 
improvements for patients starting HAART after August 2004, when 
Figure 2: Patients with toxic events and treatment modifications in 1998 
and in 2006. (A): Number of patients with each class of toxic events in 1998 
and in 2006. (B): Percentage of toxic events in patients changing HAART in 
1998 and 2006, patients interrupting HAART in 1998 and 2006 and by sex. 
*=p<0.001.
OR (95% CI)* P* OR (95%CI)** P**
Age 0.1 0.70
Male gender 0.2 0.1
IDU 2.5 (1.6-3.9) <0.001 2.0 (0.9-4.1) 0.08
<100% Adherence -- -- 11.1 (3.8-33) <0.001
HAART change 1.8 (1.0-3.2) 0.03 0.4
Any toxicity 0.2 2.0 (0.9-4.5) 0.08
Treated in 1998 3.6 (2.2-5.7) <0.001 3.1(1.5-6.3) 0.003
* Logistic regression model including 514 observations, with an area under the 
ROC curve = 0.74 and a Hosmer-Lemeshow goodness of fit test p-value= 0.3. ** 
Logistic regression model including only those patients for whom adherence data 
were available (n=255), with an area under the ROC curve = 0.80 and a Hosmer-
Lemeshow goodness of fit test p-value= 0.5.
Table 3: Logistic regression predicting virological failure at 48 weeks.
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once-daily regimens became available [35].
 
Median durability of the 
initial HAART regimen was 263 days longer in patients initiating 
HAART after that time threshold than before, the time period of 
initiating HAART was no longer associated with regimen longevity, 
however, once dosing frequency was accounted for, suggesting that 
once-daily regimens may lead to greater durability [35].
Strictly considered in view of major HAART outcomes, the most 
relevant results of our retrospection were that viral suppression and 
CD4 T-cell gains in 1998 and 2006 were very similar to those reported 
in year-matched international studies with prospective experimental 
designs [19,21], adding to the evidence that both outcomes remarkably 
improved over time for patients on their first-line HAART regimens. 
The prevalent combination of Tenofovir-based NRTI backbones 
with EFV or boosted PIs used in recent years had greater antiviral activity 
and better tolerability than first generation HAART combinations 
in many studies as in ours [36,37]; modification rates of first-line 
HAART regimens were significantly more frequent in 1998, in line 
with many other observations, even after adjusting for adherence and 
the proportion of drug addicts (data not shown) [6,7,16,18,19,35,38]. 
In our study, however, the incidence of toxic events in the sample 
years was surprisingly similar, differing from those of previous studies 
[35,39] and in line with another recent report [19]. This may be partly 
related to the epidemiological trends and clinical differences evidenced 
in the 2 sample populations, as the higher proportion of younger and 
less advanced patients in 1998 may have possibly counterbalanced 
the higher toxicity of first generation drugs used in that year [40,41]. 
Interestingly, the incidence of changes in the initial HAART regimen 
due to drug toxicity was similar in 1998 and in 2006. Using multivariate 
analyses, we tried to address the efficacy of more recent HAART 
regimens adjusting for toxicity, durability and adherence rates. Indeed, 
we found that being treated in 1998 independently predicted treatment 
failure (defined as a combination of lack or loss of viral response at 48 
w) after adjusting for many potentially relevant predictors. Identical 
results were obtained when separate analyses were carried out for lack 
and loss of viral response at 48 w, as well as when patients pretreated 
with mono or dual antiretroviral regimens were excluded (data not 
shown). So, with the limitations inherent in the retrospective design of 
this study, our data provide an additional line of evidence that HAART 
potency increased over years [14,19,20,29], even in HIV patients 
treated in general clinical practice. Interestingly, none of the patients in 
2006 was treated either with the new co-formulated NRTI backbones, 
introduced in the Italian practice after 2006, or with new generation 
PIs, including Darunavir, or with any drug in newer antiretroviral 
classes (Integrase and CCR5 Inhibitors); finally, only 3 patients received 
Enfuvirtide in their first line regimen in 2006 [35].
Our study has several limitations. Its retrospective design might 
have lead to sampling bias in the assembly of the patients’ populations 
considered for the 2 sample years. This was minimized, however, by 
allowing participation only to sites where data relative to both sample 
years were available in the same format and could be consequently 
retrieved in the same way. Furthermore, all contributing sites stated 
that all evaluable patients for both sample years were included in the 
final dataset. Another limitation may be related to the lumping of 
adherence data, which were collected in different ways at different 
sites. However, to minimize misclassifications, data on adherence were 
considered only for those patients with at least 2 evaluations available 
over follow  up; furthermore, data were dichotomized in the simplest 
possible way, classifying as potentially non-adherent all patients with 
less than optimal adherence reported at any time. A further, limitation 
may be represented by the different thresholds used in the 2 sample 
years for viral suppression. Should this limitation have any impact, 
however, it would lead to an overestimation of successes in 1998, as 
for that year any patient below 400 copies/mL at 48w was considered 
as a success. Our major result of better viral suppression rates in 2006 
would therefore, be likely strengthened by a tighter definition of 
successes in 1998. In conclusion, our investigation provides additional 
evidence that HAART success rates remarkably increased in ordinary 
Italian clinical settings in 2006 relative to 1998, yet in a homogeneously 
unfavorable epidemiological scenario of more frequent late 
presentation and later start of the first-line of HAART. Our results may 
prove of particular interest for resource poor clinical settings, where 
more recent antiretrovirals and co-formulations of antiretrovirals may 
be less frequently available.
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